Antidepressant effects of total iridoids of Valeriana jatamansi via the intestinal flora-blood-brain barrier pathway
CONTEXT: Valeriana jatamansi Jones [syn. V. wallichii DC, (Valerianaceae)] (VJJ) is used to treat depression.
OBJECTIVE: To explore the effects of total iridoids of VJJ extract (TIV) on chronic unpredictable mild stress (CUMS) in mice.
MATERIALS AND METHODS: VJJ roots and rhizomes were extracted with 70% ethanol. CUMS rats were treated daily with fluoxetine (2.6 mg/kg, i.g.) or TIV (5.7, 11.4, and 22.8 mg/kg, i.g.) for 14 days. Male Kun Ming mice on normal chow and 0.5% CMC-Na solution were used as a control. Behavioural tests included the tail suspension (TST) and sucrose preference tests (SPT). Evans blue staining was used to evaluate blood-brain barrier (BBB) permeability. Western blotting was used to measure zonula occludens-1 (ZO-1) and occludin expression. 16S rRNA sequencing was used to analyse intestinal flora abundance. Tax4Fun was used to predict KEGG metabolic pathways.
RESULTS: TIV treatment reduced TST time (117.35 ± 8.23 or 108.95 ± 6.76 vs. 144.45 ± 10.30 s), increased SPT (55.83 ± 7.24 or 53.12 ± 13.85 vs. 38.98 ± 5.43%), increased the abundance of phylum Firmicutes (86.99 ± 0.03 vs. 60.88 ± 0.19%) and genus Lactobacillus (75.20 ± 0.19 vs. 62.10 ± 0.13%), reduced the abundance of phylum Bacteroidetes (6.69 ± 0.06 or 11.50 ± 0.09 vs. 25.07 ± 0.20%). TIV increased carbohydrate metabolism (14.50 ± 3.00 × 10-3 or 14.60 ± 2.00 × 10-3 or 14.90 ± 2.00 × 10-3 vs.13.80 ± 4.00 × 10-3%), replication and repair functions (5.60 ± 1.00 × 10-3 or 5.60 ± 1.00 × 10-3 vs. 5.10 ± 4.00 × 10-3%), reduced the frequency of infectious disease (1.60 ± 2.00 × 10-4 or 1.90 ± 5.00 × 10-4 or 1.80 ± 3.00 × 10-4 vs. 2.20 ± 7.00 × 10-3%), BBB permeability (0.77 ± 0.30 vs. 1.81 ± 0.33 μg/g), and up-regulated the expression of ZO-1 (1.42-fold, 1.60-fold, 1.71-fold) and occludin (1.79-fold, 2.20-fold).
CONCLUSIONS: TIV may modulate the intestinal flora, thereby inducing the expression of ZO-1 and occludin, protecting the BBB and exerting an antidepressant effect.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Pharmaceutical biology - 59(2021), 1 vom: 03. Dez., Seite 912-921 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Li [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.12.2021 Date Revised 29.10.2023 published: Print ErratumIn: Pharm Biol. 2023 Dec;61(1):1107. - PMID 37449769 Citation Status MEDLINE |
|---|
| doi: |
10.1080/13880209.2021.1944222 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327822783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327822783 | ||
| 003 | DE-627 | ||
| 005 | 20231225201632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13880209.2021.1944222 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327822783 | ||
| 035 | |a (NLM)34236293 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antidepressant effects of total iridoids of Valeriana jatamansi via the intestinal flora-blood-brain barrier pathway |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2021 | ||
| 500 | |a Date Revised 29.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Pharm Biol. 2023 Dec;61(1):1107. - PMID 37449769 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Valeriana jatamansi Jones [syn. V. wallichii DC, (Valerianaceae)] (VJJ) is used to treat depression | ||
| 520 | |a OBJECTIVE: To explore the effects of total iridoids of VJJ extract (TIV) on chronic unpredictable mild stress (CUMS) in mice | ||
| 520 | |a MATERIALS AND METHODS: VJJ roots and rhizomes were extracted with 70% ethanol. CUMS rats were treated daily with fluoxetine (2.6 mg/kg, i.g.) or TIV (5.7, 11.4, and 22.8 mg/kg, i.g.) for 14 days. Male Kun Ming mice on normal chow and 0.5% CMC-Na solution were used as a control. Behavioural tests included the tail suspension (TST) and sucrose preference tests (SPT). Evans blue staining was used to evaluate blood-brain barrier (BBB) permeability. Western blotting was used to measure zonula occludens-1 (ZO-1) and occludin expression. 16S rRNA sequencing was used to analyse intestinal flora abundance. Tax4Fun was used to predict KEGG metabolic pathways | ||
| 520 | |a RESULTS: TIV treatment reduced TST time (117.35 ± 8.23 or 108.95 ± 6.76 vs. 144.45 ± 10.30 s), increased SPT (55.83 ± 7.24 or 53.12 ± 13.85 vs. 38.98 ± 5.43%), increased the abundance of phylum Firmicutes (86.99 ± 0.03 vs. 60.88 ± 0.19%) and genus Lactobacillus (75.20 ± 0.19 vs. 62.10 ± 0.13%), reduced the abundance of phylum Bacteroidetes (6.69 ± 0.06 or 11.50 ± 0.09 vs. 25.07 ± 0.20%). TIV increased carbohydrate metabolism (14.50 ± 3.00 × 10-3 or 14.60 ± 2.00 × 10-3 or 14.90 ± 2.00 × 10-3 vs.13.80 ± 4.00 × 10-3%), replication and repair functions (5.60 ± 1.00 × 10-3 or 5.60 ± 1.00 × 10-3 vs. 5.10 ± 4.00 × 10-3%), reduced the frequency of infectious disease (1.60 ± 2.00 × 10-4 or 1.90 ± 5.00 × 10-4 or 1.80 ± 3.00 × 10-4 vs. 2.20 ± 7.00 × 10-3%), BBB permeability (0.77 ± 0.30 vs. 1.81 ± 0.33 μg/g), and up-regulated the expression of ZO-1 (1.42-fold, 1.60-fold, 1.71-fold) and occludin (1.79-fold, 2.20-fold) | ||
| 520 | |a CONCLUSIONS: TIV may modulate the intestinal flora, thereby inducing the expression of ZO-1 and occludin, protecting the BBB and exerting an antidepressant effect | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a bacteroidetes | |
| 650 | 4 | |a blood–brain barrier (BBB) permeability | |
| 650 | 4 | |a firmicutes | |
| 650 | 4 | |a functional prediction | |
| 650 | 4 | |a lactobacillus | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Iridoids |2 NLM | |
| 650 | 7 | |a Occludin |2 NLM | |
| 650 | 7 | |a Ocln protein, mouse |2 NLM | |
| 650 | 7 | |a Plant Extracts |2 NLM | |
| 650 | 7 | |a Tjp1 protein, mouse |2 NLM | |
| 650 | 7 | |a Zonula Occludens-1 Protein |2 NLM | |
| 650 | 7 | |a Fluoxetine |2 NLM | |
| 650 | 7 | |a 01K63SUP8D |2 NLM | |
| 650 | 7 | |a Valeriana extract |2 NLM | |
| 650 | 7 | |a JWF5YAW3QW |2 NLM | |
| 700 | 1 | |a Wang, Liwen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yanni |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Hongling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Binglong |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Lingmiao |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tinglan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Liudai |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Lanlan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Guihua |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Qiaozhi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yunhui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tiane |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Zhiyong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical biology |d 1997 |g 59(2021), 1 vom: 03. Dez., Seite 912-921 |w (DE-627)NLM097504416 |x 1744-5116 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2021 |g number:1 |g day:03 |g month:12 |g pages:912-921 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13880209.2021.1944222 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2021 |e 1 |b 03 |c 12 |h 912-921 | ||